SHIFT AI Newsroom · GLOBAL
Clinical Trial Update: Cagrilintide and Semaglutide for Overweight or Obesity
A research study is comparing blood levels of Cagrilintide and Semaglutide after single doses of different versions of injectable CagriSema in adults with overweight or obesity.
A clinical trial has been registered to compare the blood levels of Cagrilintide and Semaglutide after single doses of different versions of injectable CagriSema in adults with overweight or obesity. The trial is currently in the clinical trial stage, and its potential impact and availability in the UK are unknown.
What this means in the UK
This trial may potentially lead to new treatment options for adults with overweight or obesity in the UK, but its impact and availability in the UK are currently unknown.
Known facts
- A research study is comparing blood levels of Cagrilintide and Semaglutide after single doses of different versions of injectable CagriSema in adults with overweight or obesity.